RTP-based Oriel Therapeutics (www.orieltherapeutics.com), a drug development company, has closed on $26.5 million in Series C financing led by New Leaf Venture Partners of New York and California. The company has received several patents for its technology of drug delivery through inhalers. The company, founded in 2002, uses technology that was first developed at the University of North Carolina at Chapel Hill.
Oriel Therapeutics is a CED member.